# EyePoint, Inc. (EYPT)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/eyepoint-inc/ JSON: https://steadybase.io/company/eyepoint-inc.json Checked Nov 10, 2026. Latest filing read: Aug 5, 2026.

## Company

- Legal name: EyePoint, Inc.
- Ticker: EYPT (Nasdaq)
- SEC CIK: 0001314102
- Industry: Laboratory Analytical Instruments (SIC 3826)
- Headquarters: Watertown, MA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: eyepoint.bio
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $31.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/0001193125-26-093917-index.html
- Operating income: -$243.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/0001193125-26-093917-index.html
- Net income: -$232.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/0001193125-26-093917-index.html
- SG&A: $51.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/0001193125-26-093917-index.html
- Employees: 214 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm
- Shares outstanding: 86,212,138 as of Jul 31, 2026 (10-Q filed Aug 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/0001193125-26-335037-index.html
- Auditor: Deloitte & Touche LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm

## Business

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $31.4M | -$243.4M | -$232.0M | $51.7M |
| Dec 31, 2024 | $43.3M | -$145.9M | -$130.9M | $52.5M |
| Dec 31, 2023 | $46.0M | -$75.1M | -$70.8M | $51.8M |
| Dec 31, 2022 | $41.4M | -$99.6M | -$102.3M | $60.3M |
| Dec 31, 2021 | $36.9M | -$55.3M | -$58.4M | $53.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/eyepoint-inc.json

## Officers and directors

- Jay S. Duker, President and CEO. LinkedIn: https://linkedin.com/in/jay-duker-9b3ba52. Source: Form 4 filed Jul 14, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000163086426000010/0001630864-26-000010-index.htm
- George Elston, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/george-elston-7a24247. Source: Form 4 filed Aug 24, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000142993226000010/0001429932-26-000010-index.htm
- Ramiro Ribeiro, Chief Medical Officer. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000201362326000012/0002013623-26-000012-index.htm
- Michael Campbell, Chief Commercial Officer. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm
- Reginald J. Sanders, M.D., FASRS, Director. Source: 10-K filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm
- Jay S. Duker, M.D, Board member (per proxy). Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000119312526182035/eypt-20260427.htm
- Ramiro Ribeiro, M.D., PhD, Named in proxy. Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000119312526182035/eypt-20260427.htm
- Wendy DiCicco, Board member (per proxy). Source: DEF 14A filed Apr 27, 2026, https://www.sec.gov/Archives/edgar/data/1314102/000119312526182035/eypt-20260427.htm

## Recent 8-K events

- Oct 19, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 2.05, Costs associated with exit or disposal activities (restructuring); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm
- Oct 19, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm
- Sep 10, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm
- Aug 17, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-20260805.htm
- Jul 30, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm
- Jul 17, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526307792/eypt-20260713.htm
- Jun 22, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526276688/eypt-20260618.htm
- May 14, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-20260514.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/eypt-20260506.htm

## Insider trades (Form 4)

- Aug 18, 2026: Karen L. Zaderej (Director) bought 10,600 shares, about $52,258. Source: https://www.sec.gov/Archives/edgar/data/1314102/000153096826000004/0001530968-26-000004-index.htm
- Jun 30, 2026: Ramiro Ribeiro (Chief Medical Officer) sold 4,875 shares, about $73,174. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362326000012/0002013623-26-000012-index.htm
- Apr 17, 2026: Ramiro Ribeiro (Chief Medical Officer) sold 2,437 shares, about $36,555. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362326000010/0002013623-26-000010-index.htm
- Mar 16, 2026: Jay S. Duker (President and CEO) bought 1,500 shares, about $19,725. Source: https://www.sec.gov/Archives/edgar/data/1314102/000163086426000006/0001630864-26-000006-index.htm
- Mar 4, 2026: Ramiro Ribeiro (Chief Medical Officer) sold 2,438 shares, about $43,567. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362326000008/0002013623-26-000008-index.htm
- Feb 17, 2026: Ramiro Ribeiro (Chief Medical Officer) sold 2,437 shares, about $36,555. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362326000006/0002013623-26-000006-index.htm
- Jan 5, 2026: Ramiro Ribeiro (Chief Medical Officer) sold 42,544 shares, about $727,502. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362326000004/0002013623-26-000004-index.htm
- Dec 4, 2025: Nancy Lurker (Director) sold 9,300 shares, about $140,523. Source: https://www.sec.gov/Archives/edgar/data/1314102/000145048525000009/0001450485-25-000009-index.htm
- Nov 28, 2025: Nancy Lurker (Director) sold 700 shares, about $10,465. Source: https://www.sec.gov/Archives/edgar/data/1314102/000145048525000007/0001450485-25-000007-index.htm
- Nov 11, 2025: Ramiro Ribeiro (Chief Medical Officer) sold 2,722 shares, about $31,602. Source: https://www.sec.gov/Archives/edgar/data/1314102/000201362325000005/0002013623-25-000005-index.htm

## Latest filings

- 8-K filed Oct 19, 2026: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm
- 10-K filed Mar 5, 2026: https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm
- DEF 14A filed Apr 27, 2026: https://www.sec.gov/Archives/edgar/data/1314102/000119312526182035/eypt-20260427.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/